Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27837565 | 0.93 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2KMT2AHPGDKCNJ1 | |
| SCHEMBL31696858 | 0.88 | CTSB (0.52) | ALDH1A1SMN1; SMN2KMT2AKCNJ1KDM4E | |
| SCHEMBL31696865 | 0.81 | CTSB (0.54) | ALDH1A1SMN1; SMN2KMT2AKCNJ1KDM4E | |
| SCHEMBL11613240 | 0.81 | ALDH1A1 (0.51) | ALDH1A1HPGDLMNATDP1 | |
| SCHEMBL32662599 | 0.80 | CYP1A2 (0.46) | ALDH1A1SMN1; SMN2KMT2AHPGDGAA | |
| SCHEMBL27837694 | 0.79 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2KMT2AHPGDKCNJ1 | |
| SCHEMBL17048085 | 0.79 | ALDH1A1 (0.49) | ALDH1A1LMNATDP1 | |
| SCHEMBL17048086 | 0.79 | ALDH1A1 (0.49) | ALDH1A1LMNATDP1 | |
| SCHEMBL20299855 | 0.78 | BCL9 (0.44) | ALDH1A1SMN1; SMN2KMT2AHPGDLMNA | |
| SCHEMBL5857278 | 0.78 | SIGMAR1 (0.48) | ALDH1A1SMN1; SMN2KMT2AKDM4ESIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030123-B2 | Indole derivatives with vascular damaging activity | ASTRAZENECA AB (SE) | 2006-04-18 | — | — | US | disclosed |
| US-20030216356-A1 | Indole derivatives with vascular damaging activity | ASTRAZENECA AB (SE) | 2003-11-20 | — | — | US | disclosed |
| EP-1289952-A1 | INDOLE DERIVATIVES WITH VASCULAR DAMAGING ACTIVITY | AstraZeneca AB (SE) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001092224-A1 | INDOLE DERIVATIVES WITH VASCULAR DAMAGING ACTIVITY | ASTRAZENECA AB (SE) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216356-A1 | Indole derivatives with vascular damaging activity | IDO1, IDO2, VEGFA | ALDH1A1 1818/4885SMN1; SMN2 4561/4885KMT2A 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.